The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of atezolizumab combined with cisplatin and vinorelbine as adjuvant therapy for completely resected non-small cell lung cancer with EGFR mutation (WJOG11719L: ADJUST study).
 
Yoshihiro Miyata
No Relationships to Disclose
 
Ryota Shibaki
No Relationships to Disclose
 
Hiroaki Akamatsu
Honoraria - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Janssen; Kyowa Kirin International; Lilly; MSD; Nippon Kayaku; Novartis; Novocure; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; GlaxoSmithKline; Janssen; Sandoz
Research Funding - Amgen (Inst); Chugai Pharma (Inst); Novartis (Inst)
 
Mitsuo Osuga
No Relationships to Disclose
 
Yasuhiro Koh
Honoraria - Amgen; Chugai Pharma; Cytogen; Guardant Health; Novartis; Tosoh Corporation
Consulting or Advisory Role - Tosoh Corporation
Research Funding - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Takeda (Inst); Zeon Corporation
 
Kenta Murotani
Speakers' Bureau - Astrazeneca; Chugai Pharma; MSD; Nippon Shinyaku; Pfizer; Taiho Pharmaceutical
 
Kazumi Nishino
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; Lilly Japan; Merck; Nippon Boehringer Ingelheim; Nippon Kayaku; Novar Pharma; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Lilly Japan; Pfizer
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer Pharma Japan. (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Delta-Fly Pharma (Inst); EPS Corporation (Inst); Fortrea Japan (Inst); Gilead Sciences (Inst); IQvia (Inst); Janssen (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Parexel International Inc (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - Amgen; Boehringer Ingelheim; Chugai Pharma; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; DaiichiSankyo; Johnson & Johnson/Janssen; Merck KGaA; MSD; Novocure
Research Funding - Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Bayer; BeiGene (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Johnson & Johnson/Janssen (Inst); Lilly (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Novocure (Inst); Pfizer (Inst); Regeneron (Inst); Takeda (Inst)
 
Kazushige Wakuda
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD (Inst)
 
Tetsuya Mitsudomi
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Ethicon; Guardant Health; Janssen Oncology; Kyowa Hakko Kirin; Lilly; Merck KGaA; MSD K.K; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Thermofisher Scientific Biomarkers
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol Myers Squibb; MSD Oncology; Ono Pharmaceutical; Regeneron
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bridgebio (Inst); Chugai Pharma (Inst); MSD K.K (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Kenichi Yoshimura
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Eisai; Lilly; Nihon-Shinyaku; Nihonkayaku; Novartis; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - BrightPath Biotheraputics; Nippon Shinyaku; Sysmex
 
Nobuyuki Yamamoto
Honoraria - Abbvie; Acuuray; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Guardant Health; Janssen; Kyorin; Kyowa Kirin International; Lilly Japan; Merck; Miyarisan pharmaceutical; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.
Consulting or Advisory Role - Amgen; AstraZeneca; Chugai Pharma; MSD; Novartis; Ono Pharmaceutical
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); EPS Corporation (Inst); IQvia (Inst); Janssen (Inst); Lilly Japan (Inst); Mebix (Inst); Medpace (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Prime-R (Inst); Syneos Health (Inst)